Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decline in Short Interest

Black Diamond Therapeutics, Inc. (NASDAQ:BDTXGet Free Report) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 2,400,000 shares, a decrease of 33.0% from the January 15th total of 3,580,000 shares. Based on an average daily trading volume, of 528,500 shares, the short-interest ratio is presently 4.5 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, November 22nd.

Get Our Latest Report on Black Diamond Therapeutics

Black Diamond Therapeutics Trading Up 2.6 %

BDTX opened at $4.34 on Tuesday. The company has a 50 day moving average of $3.03 and a 200 day moving average of $2.87. The company has a market cap of $224.10 million, a PE ratio of -2.04 and a beta of 2.59. Black Diamond Therapeutics has a 12 month low of $1.22 and a 12 month high of $6.85.

Institutional Trading of Black Diamond Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Stifel Financial Corp increased its position in shares of Black Diamond Therapeutics by 455.7% in the fourth quarter. Stifel Financial Corp now owns 111,700 shares of the company’s stock valued at $314,000 after acquiring an additional 91,600 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Black Diamond Therapeutics by 111.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 110,612 shares of the company’s stock valued at $312,000 after buying an additional 58,354 shares during the period. Jump Financial LLC increased its position in shares of Black Diamond Therapeutics by 245.0% during the fourth quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after buying an additional 27,616 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in shares of Black Diamond Therapeutics during the fourth quarter valued at about $233,000. Finally, Vanguard Group Inc. boosted its stake in Black Diamond Therapeutics by 32.6% during the third quarter. Vanguard Group Inc. now owns 1,963,583 shares of the company’s stock worth $5,635,000 after acquiring an additional 482,198 shares in the last quarter.

Black Diamond Therapeutics Company Profile

(Get Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.

See Also

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.